Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Modeling anti-IL-6 therapy using breast cancer patient-derived xenografts

  • Morancho, Beatriz|||0000-0003-3369-8647
  • Zacarías-Fluck, Mariano F|||0000-0002-7171-4268
  • Esgueva, Antonio|||0000-0002-8622-064X
  • Bernadó Morales, Cristina|||0000-0003-1376-0407
  • Cosimo, Serena Di
  • Prat, Aleix|||0000-0003-2377-540X
  • Cortés Castán, Javier|||0000-0001-7623-1583
  • Arribas, Joaquín V|||0000-0002-0504-0664
  • Rubio, Isabel T.|||0000-0003-0035-0679
The pleiotropic cytokine IL-6 accelerates the progression of breast cancer in a variety of preclinical models through the activation of the STAT3 (signal transducer and activator of transcription 3) signaling pathway. However, the proportion of breast cancers sensitive to anti-IL-6 therapies is not known. This study evaluates the efficacy of anti-IL-6 therapies using breast cancer patient derived xenografts (PDXs). During the generation of our collection of PDXs, we showed that the successful engraftment of tumor tissue in immunodeficient mice correlates with bad prognosis. Four PDXs out of six were resistant to anti-IL-6 therapies and the expression of IL-6, its receptor or the levels of phospho-STAT3 (the active form of the signal transducer) did not correlate with sensitivity. Using cell cultures established from the PDXs as well as samples from in vivo treatments, we showed that only tumors in which the activation of STAT3 depends on IL-6 respond to the blocking antibodies. Our results indicate that only a fraction of breast tumors are responsive to anti-IL-6 therapies. In order to identify responsive tumors, a functional assay to determine the dependence of STAT3 activation on IL-6 should be performed.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies

  • Vicario, Rocío
  • Peg, Vicente|||0000-0002-5203-6166
  • Morancho, Beatriz|||0000-0003-3369-8647
  • Zacarías-Fluck, Mariano F|||0000-0002-7171-4268
  • Zhang, Junjie
  • Martínez-Barriocanal, Águeda|||0000-0002-8809-160X
  • Navarro Jiménez, Alexandra
  • Aura, Claudia
  • Burgués, Octavio|||0000-0002-2471-5516
  • Lluch, Ana|||0000-0003-2766-407X
  • Cortés Castán, Javier|||0000-0001-7623-1583
  • Nuciforo, Paolo|||0000-0003-1380-0990
  • Rubio, Isabel T.|||0000-0003-0035-0679
  • Marangoni, Elisabetta
  • Deeds, James
  • Boehm, Markus
  • Schlegel, Robert
  • Boehm, Markus
  • Tabernero, Josep|||0000-0002-2495-8139
  • Mosher, Rebecca
  • Boehm, Markus
  • Arribas, Joaquín V|||0000-0002-0504-0664
A chromosomal region that includes the gene encoding HER2, a receptor tyrosine kinase (RTK), is amplified in 20% of breast cancers. Although these tumors tend to respond to drugs directed against HER2, they frequently become resistant and resume their malignant progression. Gene amplification in double minutes (DMs), which are extrachromosomal entities whose number can be dynamically regulated, has been suggested to facilitate the acquisition of resistance to therapies targeting RTKs. Here we show that ~30% of HER2-positive tumors show amplification in DMs. However, these tumors respond to trastuzumab in a similar fashion than those with amplification of the HER2 gene within chromosomes. Furthermore, in different models of resistance to anti-HER2 therapies, the number of DMs containing HER2 is maintained, even when the acquisition of resistance is concomitant with loss of HER2 protein expression. Thus, both clinical and preclinical data show that, despite expectations, loss of HER2 protein expression due to loss of DMs containing HER2 is not a likely mechanism of resistance to anti-HER2 therapies
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Role of ADAM17 in the non-cell autonomous effects of oncogene-induced senescence

  • Morancho, Beatriz|||0000-0003-3369-8647
  • Martínez-Barriocanal, Águeda|||0000-0002-8809-160X
  • Villanueva, Josep|||0000-0003-1396-9470
  • Arribas, Joaquín V.|||0000-0002-0504-0664
Cellular senescence is a terminal cell proliferation arrest that can be triggered by oncogenes. One of the traits of oncogene-induced senescence (OIS) is the so-called senescence-associated secretory phenotype or senescence secretome. Depending on the context, the non-cell autonomous effects of OIS may vary from tumor suppression to promotion of metastasis. Despite being such a physiological and pathologically relevant effector, the mechanisms of generation of the senescence secretome are largely unknown. We analyzed by label-free proteomics the secretome of p95HER2-induced senescent cells and compared the levels of the membrane-anchored proteins with their transcript levels. Then, protein and RNA levels of ADAM17 were evaluated by using Western blot and reverse transcription-polymerase chain reaction, its localization by using biotin labeling and immunofluorescence, and its activity by using alkaline phosphatase-tagged substrates. The p95HER2-expressing cell lines, senescent MCF7 and proliferating MCF10A, were analyzed to study ADAM17 regulation. Finally, we knocked down ADAM17 to determine its contribution to the senescence-associated secretome. The effect of this secretome was evaluated in migration assays in vitro and in nude mice by assessing the metastatic ability of orthotopically co-injected non-senescent cells. Using breast cancer cells expressing p95HER2, a constitutively active fragment of the proto-oncogene HER2 that induces OIS, we show that the extracellular domains of a variety of membrane-bound proteins form part of the senescence secretome. We determine that these proteins are regulated transcriptionally and, in addition, that their shedding is limited by the protease ADAM17. The activity of the sheddase is constrained, at least in part, by the accumulation of cellular cholesterol. The blockade of ADAM17 abrogates several prometastatic effects of the p95HER2-induced senescence secretome, both in vitro and in vivo. Considering these findings, we conclude that ectodomain shedding is tightly regulated in oncogene-induced senescent cells by integrating transcription of the shedding substrates with limiting ADAM17 activity. The remaining activity of ADAM17 contributes to the non-cell autonomous protumorigenic effects of p95HER2-induced senescent cells. Because ADAM17 is druggable, these results represent an approximation to the pharmacological regulation of the senescence secretome. The online version of this article (doi:10.1186/s13058-015-0619-7) contains supplementary material, which is available to authorized users.